AIM2 Promotes Gastric Cancer Cell Proliferation Via the MAPK Signaling Pathway

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2022 Apr 18

PMID 35432843

Authors

Xiaojia Feng

Zaozhi Song

Qihui Huang

Jianguang Jia

Lingmei Zhang

Mengqi Zhu

Jun Qian

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) is a highly prevalent tumor type. The dysregulated expression of melanoma deficiency factor 2 (AIM2) has been observed in a range of tumor types. Herein, we explore the role of AIM2 in the regulation of GC progression.

Methods: Gastric cancer cells BGC-823 and MGC-803 in logarithmic growth phase were divided into blank group (control), Control group (NC) and SH-AIM2 group, respectively. Control group and SH-AIM2 group were transfected with AIM2 NC and SH-AIM2, respectively. Nude mice were divided into blank group (control) and SH-AIM2 group, and the treatment methods were the same as above. Differential AIM2 expression in GC tissues was assessed via bioinformatics analyses, after which western blotting was used for analyzing the AIM2 levels in tumor and paracancerous tissues from five stomach cancer patients. In addition, qPCR and protein imprinting were used to assess AIM2 expression levels in GC cells, and AIM2 knockdown was conducted in MGC-803 and BGC-823cells, after which colony formation and EdU incorporation assay were utilized to assess cell proliferation. The oncogenic role of AIM2 was then assessed in mice and validated through immunohistochemical analyses.

Results: GC tissues and cell lines exhibited marked AIM2 overexpression. AIM2 knockdown significantly impaired GC cell proliferation and migration, as confirmed through assays. In vivo experiments showed that both the increment ability and invasion and migration ability of AIM2 knockdown group were significantly lower than that of control and NC the change of AIM2 protein level would affect the change of MAPK pathway related protein level.

Conclusions: AIM2 knockdown markedly suppresses the proliferation, migration, as well as invasion of GC cells via the inhibition of MAPK signaling, thereby slowing tumor progression. Overall, these results suggest that further analyses of AIM2 may offer clinically valuable insights that can aid in the treatment of human GC.

Citing Articles

Comprehensive analysis of disulfidptosis related genes and prognosis of gastric cancer.

Li Q, Yin L World J Clin Oncol. 2023; 14(10):373-399.

PMID: 37970110 PMC: 10631345. DOI: 10.5306/wjco.v14.i10.373.

Prognostic and immunotherapeutic significance of immunogenic cell death-related genes in colon adenocarcinoma patients.

Xu J, Yang J, Pan X, Wang J Sci Rep. 2023; 13(1):19188.

PMID: 37932362 PMC: 10628212. DOI: 10.1038/s41598-023-46675-y.

Retracted: AIM2 Promotes Gastric Cancer Cell Proliferation via the MAPK Signaling Pathway.

Healthcare Engineering J J Healthc Eng. 2023; 2023:9839615.

PMID: 37388128 PMC: 10307078. DOI: 10.1155/2023/9839615.

AIM2 and Psoriasis.

Zhang Y, Xu X, Cheng H, Zhou F Front Immunol. 2023; 14:1085448.

PMID: 36742336 PMC: 9889639. DOI: 10.3389/fimmu.2023.1085448.

Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines.

Krushkal J, Vural S, Jensen T, Wright G, Zhao Y Clin Epigenetics. 2022; 14(1):161.

PMID: 36461044 PMC: 9716673. DOI: 10.1186/s13148-022-01368-7.

References

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

Akter H, Park M, Kwon O, Song E, Park W, Kang M . Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 2015; 36(8):6053-62. DOI: 10.1007/s13277-015-3282-9. View

Fu L, Dong Q, He J, Wang X, Xing J, Wang E . SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. Oncogene. 2016; 36(19):2724-2736. DOI: 10.1038/onc.2016.425. View

Li P, Xue W, Feng Y, Mao Q . Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. Am J Transl Res. 2016; 8(8):3522-9. PMC: 5009404. View

Yang M, Huang C . Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol. 2015; 21(41):11673-9. PMC: 4631968. DOI: 10.3748/wjg.v21.i41.11673. View

Yang S, Sharrocks A, Whitmarsh A . Transcriptional regulation by the MAP kinase signaling cascades. Gene. 2003; 320:3-21. DOI: 10.1016/s0378-1119(03)00816-3. View

Dong Z . [Preparation and identification of monoclonal antibody against the gastric cancer cell line MGC 803]. Zhonghua Zhong Liu Za Zhi. 1986; 8(1):8-10. View

Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J . Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int J Cancer. 2014; 135(10):2387-96. DOI: 10.1002/ijc.28891. View

Chiang S, Chen W, Ke T, Chen T, You Y, Lin C . HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer. Cell Death Dis. 2018; 9(10):1004. PMC: 6158296. DOI: 10.1038/s41419-018-1019-6. View

10.

Woerner S, Kloor M, Schwitalle Y, Youmans H, von Knebel Doeberitz M, Gebert J . The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer. 2007; 46(12):1080-9. DOI: 10.1002/gcc.20493. View

11.

Chen L, Wang L, Tsang N, Ojcius D, Chen C, OuYang C . Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4(12):1276-93. PMC: 3531603. DOI: 10.1002/emmm.201201569. View

12.

Fernandes-Alnemri T, Yu J, Datta P, Wu J, Alnemri E . AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009; 458(7237):509-13. PMC: 2862225. DOI: 10.1038/nature07710. View

13.

Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A . Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci. 2012; 103(4):782-90. PMC: 7659186. DOI: 10.1111/j.1349-7006.2012.02211.x. View

14.

Asefa B, Klarmann K, Copeland N, Gilbert D, Jenkins N, Keller J . The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol Dis. 2004; 32(1):155-67. DOI: 10.1016/j.bcmd.2003.10.002. View

15.

DeYoung K, Ray M, Su Y, Anzick S, Johnstone R, Trapani J . Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene. 1997; 15(4):453-7. DOI: 10.1038/sj.onc.1201206. View

16.

Deng G, Lu Y, Chen S, Miao J, Lu G, Li H . Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line. Cancer Res. 1987; 47(12):3195-8. View

17.

Ma X, Guo P, Qiu Y, Mu K, Zhu L, Zhao W . Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget. 2016; 7(24):36185-36197. PMC: 5094992. DOI: 10.18632/oncotarget.9154. View

18.

Yang G, Tao H, Wang H, Sun Y, Zhang L, Zhang C . Ara-C increases gastric cancer cell invasion by upregulating CD-147-MMP-2/MMP‑9 via the ERK signaling pathway. Oncol Rep. 2015; 33(4):2045-51. DOI: 10.3892/or.2015.3748. View

19.

Wilson J, Petrucelli A, Chen L, Koblansky A, Truax A, Oyama Y . Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nat Med. 2015; 21(8):906-13. PMC: 4529369. DOI: 10.1038/nm.3908. View

20.

Wang G, Li Y, Yang Z, Xu W, Yang Y, Tan X . ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer. Biochem Biophys Res Commun. 2018; 500(4):873-878. DOI: 10.1016/j.bbrc.2018.04.177. View